TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Utility of Subcutaneous Furosemide in Patients Presenting With Early Signs of Fluid Overload

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age≥ 18 years~* Symptomatic and chronic heart failure (NYHA Class II and III).~* Patients on guideline directed medical therapy 90 days prior to enrollment.~* Adequate home environment for at-home treatment.~* Presenting or referred to the clinic because of evidence of worsening heart failure with fluid overload (decompensation).~* A modification in oral diuretics is not clinically appropriate as deemed by the investigator.~* Estimated excess fluid weight of 4 lbs. or more from euvolemic state.~* Participant able to give informed consent for participation in trial. Agreeing to sign informed consent and HIPAA authorization.~* Understanding and willing to comply with the protocols of the trial.~* Ability of the participant or caregiver to independently apply the investigational device and medication~Exclusion Criteria:~* ACC/AHA Stage D heart failure or patients requiring IV inotrope therapy.~* Massive volume overload (e.g. \>20 lbs. of estimated fluid weight) or anasarca.~* Suspected high risk clinical instability with outpatient treatment.~* Pregnant females or women of child-bearing age who are not willing to use an adequate form of contraception.~* Chronic Obstructive Pulmonary Disease (COPD) moderate or worse: FEV1/FCV ratio \<0.7 and FEV1 \<60 percent predicted.~* Rapid atrial fibrillation (AF) (HR \>100b/min)~* Hypoxia (resting O2 saturation \<90%).~* Hypotension (systolic blood pressure (SBP) BP \< 90 mmHg).~* Uncontrolled diabetes mellitus (DM) (admission glucose levels \> 300 mg/dL).~* Advanced renal disease (eGFR \< 30mL/min/1.73m2).~* Acute coronary syndrome.~* Serum potassium (K) \<3.2 mmol/L or \> 5.5mmol/L.~* On experimental medication or currently participating in an interventional cardiovascular research study, other than an observational or registry study.~* Having received intravenous furosemide within 24 hours prior to enrollment.~* Urinary tract abnormality or disorder interfering with urination.~* Allergy to the active and inactive ingredients of the study medication.~* Inability to comply with study requirements.~* Ongoing substance abuse.~* Concern that the current episode of decompensation was precipitated by a serious medical condition which may require additional evaluation or treatment.~* Dementia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- In-Home Subcutaneous Furosemide Treatment ARm (Type: EXPERIMENTAL): Prospective, open-label arm to evaluate the clinical effectiveness of a novel formulation of furosemide delivered by subcutaneous administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Inflammatory Symptoms Reduction With Amoxicillin + Ketoprofen in Acute Pharyngeal Tonsillitis in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Quick-test positive for Streptococcus pyogenes;~* Indication for treatment with amoxicillin according to labeling and physician's clinical evaluation;~* Pain (for swallowing) evaluated by Wong Baker Faces Pain scale with at least grade 3;~* Presence of at least two of the follow symptoms:~  * Hyperemia and edema evaluated with at least 2 out of 4 crosses~ * Fever in the previous 48 hours~ * Cervical adenomegaly~ * Tonsilla with erythema or erythema and white exsudate.~Exclusion Criteria:~* History of cardiovascular, gastrointestinal, metabolic or psychiatric conditions;~* History and laboratorial confirmation of hematologic, hepatic or renal disorders;~* Use of nonsteroidal antiinflammatory drugs (NSAID) during the last 3 weeks and gastroesophageal reflux during the last 6 months;~* Use of analgesic or anti inflammatory medication (except Paracetamol) in the previous 12 hours;~* History of allergy or hypersensitivity to amoxicillin and/ or ketoprofen.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Ketoprofen + Amoxicillin (Type: EXPERIMENTAL): Ketoprofen + Amoxicillin for 3 days, then Amoxicillin alone for 7 days
- Amoxicillin (Type: PLACEBO_COMPARATOR): Placebo (for ketoprofen) + Amoxicillin for 3 days, then Amoxicillin alone for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, 18 years old or older.~2. Histologically or cytologically confirmed diagnosis of a solid tumor (RCC, HCC, or colorectal cancer).~3. Participants are planning to initiate treatment with either sorafenib or regorafenib as a single chemotherapeutic agent~4. Able to swallow and retain oral medication and does not have any clinically relevant, active gastrointestinal disease or other condition that may significantly alter absorption, distribution, metabolism, or excretion of drugs.~5. Be able to provide written informed consent.~Exclusion Criteria~1. Patients who are or will be receiving other chemotherapeutic or molecularly targeted agents in addition to sorafenib or regorafenib~2. Concurrent moderate or severe chronic inflammatory skin condition (eczema, psoriasis)~3. Concurrent blistering skin disorder of any severity (such as pemphigus, bullous pemphigoid)~4. Connective tissue disorders with skin involvement (systemic lupus erythematosus, scleroderma, dermatomyositis, etc.)~5. Patients manifesting an allergic skin reaction (such as urticaria) or skin reaction as a complication of prior chemotherapy~6. Patients with skin lesions of infectious or non-infectious cause, precluding skin biopsy~7. Patients not willing to undergo skin biopsy~8. Patients who are pregnant or planning to become pregnant during their participation in the study.~9. Chemotherapy, targeted therapy, or biological therapy within two weeks of start of treatment.~10. Ability to give informed consent is compromised by cognitive and/or decisional impairment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Evaluation of Same Day Bidirectional Endoscopy for Occult Bleeding

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Outpatients referred for occult bleeding (iron deficiency or FOBT positivity)~Exclusion Criteria:~* Overt bleeding (melena, hematochezia)~* Abnormal luminal imaging~* Prior EGD or colonoscopy within 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Co Enzyme Q10 Together With Fertility Drugs on Pregnancy Outcome of in Vitro Fertilization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 35-43 years at the time of enrollment~* Diagnosis of primary infertility~Exclusion Criteria:~* Body mass index (BMI) \> 38 kg/m2~* Early follicular phase (day 2-4) serum FSH level \> 20 mIU/ml.~* Abnormal uterine cavity as evidenced by sonohysterogram or hysterosalpingography~* Any current use of systemic steroid medication or any infertility treatment within 3 months of study enrollment.~* Any contraindication to being pregnant and carrying a pregnancy to term.~* Contraindication for the use of CoQ10, Superfact, Puregon, hCG, Estrace and Progesterone suppositories.~* Any ovarian or abdominal abnormality that may interfere with adequate TVS evaluation.~* Absence of one or two ovaries~* Clinically relevant systemic disease (e.g., Insulin-dependent diabetes, adrenal dysfunction, organic intracranial lesion, polycystic ovarian syndrome, hyperprolactinemia, or hypothalamic tumor) or serious illness (Neoplasia).~* History (within past 12 months) or current abuse of alcohol or drugs.~* Administration of any investigational drugs within three months prior to study enrollment.~* Any medical condition that may interfere with the absorption, distribution, metabolism or excretion of the study drugs, gastrointestinal diseases, mal absorption syndromes and liver dysfunction~* Unexplained gynecological bleeding.~* Ejaculated sperm is not sufficient for ICSI~* Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study.~* Abnormal COH screening blood done for both partners, including: prolactin, thyroid stimulating hormone, HIV serology, Hepatitis B and C serology, Rubella, group and screen and syphilis serology prior to participation in study.~* Unwillingness to give written informed consent. Previous entry into this study or simultaneous participation in another clinical trial.~* The concurrent use of any of the following drugs:~* Daunorubicin, Doxorubicin, Blood Pressure Medications, Warfarin, Timolol, atorvastatin, cerivastatin, lovastatin, pravastatin, simvastatin gemfibrozil, tricyclic antidepressant medications (including amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine) multivitamins or any vitamin supplementation except Folic acid.

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 43 Years
- Healthy Volunteers: t

Study Arms:
- CoQ10 (Type: EXPERIMENTAL): This group will be treated concomitantly with Coenzyme Q10
- Control (Type: PLACEBO_COMPARATOR): Treated with capsules containing the vehicle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Screening Protocol for Children and Adolescents With Attention Deficit Hyperactivity Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Males and females ages 6-17~2. Family/guardian contacting the Clinical Research Program in Pediatric Psychopharmacology, with concerns regarding ADHD symptoms in his/her child~Exclusion Criteria:~1. History of significant head trauma with loss of consciousness, organic brain disorders, seizures, or neurological intervention~2. Any significant medical condition, in the judgment of the investigator~3. Mental retardation~4. Pregnancy or lactation~5. Subjects with current, uncontrolled (within the past 3 months) illicit drug or alcohol dependence~6. Sensory difficulties such as deafness or blindness

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologic (or cytologic) proof of colorectal carcinoma (CRC).~2. Age: between 18 and 80.~3. Sex: both sexes.~4. Previous treatment for metastatic disease is limited to FOLFIRI+ bevacizumab.~5. Prior adjuvant chemotherapy, with a fluoropyrimidine and/or Oxaliplatin, is allowed.~6. Prior radiotherapy, either as adjuvant treatment or palliation of metastatic sites is allowed, provided that there are other non-irradiated foci of disease for evaluation.~7. Persistent remission, either complete, partial or minimal response (CR, PR or MR) or stable disease (SD), one year+/-one month from initiation of first line treatment for mCRC.~8. Asymptomatic patients at break from chemotherapy.~9. Intact organ function, including complete blood counts (CBC) showing normal values or any toxicity limited to grade 1 and blood chemistry (SMA) showing liver and renal functions \< 1.5 upper normal limit (UNL).~10. Capability to understand and to sign the informed consent.~Exclusion Criteria:~1. Concurrent any other cancer (except BCC or squamous cell carcinoma of skin).~2. Inability to adhere to monthly visits to the oncology unit for evaluation.~3. Presence of brain metastases.~4. Any current or recent (within the last month) continuous treatment by steroids or by NSAIDs, or with therapeutic doses of anticoagulants for any reason.~5. Previous radiotherapy to the only site of measurable disease.~6. Evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac including arrhythmias, hepatic or renal disease), and/or existence of active peptic ulcer (clinically and/or by gastroscopy).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- LDM anti-angiogenic chemotherapy (Type: EXPERIMENTAL): LDM (Low Dose Metronomic) anti-angiogenic chemotherapy includes daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE.
- observation (Type: NO_INTERVENTION): observation only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Suicide Gene Therapy Trial

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with primary immunodeficiencies, haematological malignancies or metabolic disorders at GOSH (children of both sexes, aged 0 to 16 years) undergoing haploidentical transplant~2. Both patient and donor must give informed consent in writing.~3. The donor must be willing, able and available for donation of T cells by collection of whole blood or leukapheresis.~4. The patient should be free of serious intercurrent illness.~Exclusion Criteria:~1. Donor unfit or unavailable~2. Donor positive for Hepatitis B or C, or HTLV-1, or HIV~3. Patient receiving Ganciclovir, Aciclovir, Cidofovir a result of active CMV, adenovirus, varicella zoster or herpes simplex infection infection~4. GVHD ≥ grade II before infusion of gene modified T cells~5. Serious intercurrent illness

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- HSVTK retrovirally-transduced donor T lymphocytes (Type: EXPERIMENTAL): HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD~* dose 1 5x104 cells/kg~* dose 2 5x105 cells/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cadiotocography Combined With ST-analysis Versus Cardiotocography Combined With Scalp-pH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* intermediate or abnormal CTG and~* Normal fetal scalp-pH \> or = 7,25~Exclusion Criteria:~* preterminal CTG~* Fetal arrythmias or A-V block~* Severe fetal malformations (known)~* Amnionitis (temp \> 38,5 degr. celcius)~* maternal Hepatitis B/C or HIV

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- CTG + FBS (Type: ACTIVE_COMPARATOR): intrapartum surveillance with CTG+FBS
- Neoventa S 21 ST-ANalysis of fetal heart (Type: ACTIVE_COMPARATOR): intrapartum surveillance with CTG + STAN

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hydrotherapy for the Reversal of Oligohydramnios

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Maternal Age \>18 years~* Oligohydramnios: diagnosed by sonography (defined AFV\<8cm)~* Singleton Pregnancy~* Intact membranes~* Gestational age 24 - 36 weeks~Exclusion Criteria:~* Indication for urgent delivery (severe PET, HELLP syndrome, persistent fetal hypoxemia \[non-reassuring fetal heart rate pattern\])~* Ruptured amniotic membranes; PPROM, PROM, SROM~* Fever (\>38C)~* Multiple gestation~* \>37 week gestation~* Lethal Fetal anomalies and/or demise~* Maternal Cardiovascular disease~* Maternal Renal disease~* Maternal Pulmonary disease (other than asthma)~* Patients using prostaglandin inhibitors, NSAIDs3,15 (within 1 week of enrollment, other than baby asprin)~* Non-English speaking~* Vaginal Infections and/or active skin lesions~* Placenta Previa and/or Unexplained Vaginal Bleeding~* BMI \> 45

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV/Oral Hydration and Bedrest (Type: ACTIVE_COMPARATOR): * Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~* AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs
- Hydrotherapy Group (Type: ACTIVE_COMPARATOR): * Maternal BP (sitting)~* Pulse Pressure~* Pulse~* Urine Specific Gravity BID~* Fetal Heart Rate~* Maternal Body Weight US Procedures~* AC/EFW~* Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~  o 1 hour +/- 30 minutes after submersion therapy~* Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~  o 1 hour +/- 30 minutes after submersion therapy~* AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~* 1 Liter Water PO over 2 hours~* 1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\\hr for duration of the study participation~* Strict I/O's~* Vital signs~* HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Stress on Non Surgical Periodontal Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Severe generalized chronic periodontitis~* Minimum 15 teeth~* Attachment loss \> 5mm~* 30% of sites affected- 5% of pockets\>5mm~* Bone loss- Bleeding on probing~Exclusion Criteria:~* Patient at risk of endocarditis~* Pregnant women~* Patient under therapy for depression~* Patient treated for periodontal diseases previously

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- questionary (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Painless Subconjunctival Antibiotic and Antifungal Injection in Corneal Ulcer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The corneal ulcer patients who are diagnosed by ophthalmologist and have 2 of 3 in these following features.~  1. corneal epithelial defect with stromal infiltration~ 2. reaction in anterior chamber~ 3. positive for bacteria or fungus~* The patients have to receive subconjunctival antibiotic injection twice at least.~* The patients must be informed consent.~Exclusion Criteria:~* The patients who have history of allergy of local anesthetics, antibiotics or antifungal drugs.~* The patients who administered NSAIDs or weak opioids within 24 hours prior to subconjunctival antibiotic/antifungal injection.~* Unable to cooperate with the treatment.~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NSS/Lidocaine (Type: EXPERIMENTAL): First injection: Normal saline Second injection: 2% Lidocaine without adrenaline
- Lidocaine/NSS (Type: EXPERIMENTAL): First injection: 2% Lidocaine without adrenaline Second injection: Normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues